Royalty Pharma plc
RPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001802768
In the last 90 days, Royalty Pharma plc insiders filed 0 open-market purchases and 5 sales; 650 institutions reported holding it in 13F filings for Q2 2026, worth $20.6B in total; Dorsey Asset Management is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Royalty Pharma plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 3 insiders, $20.3M in total
- Insiders trading
- 3
- Net value
- −$20.3M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Royalty Pharma plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering | 270,401Indirect | Sep 24, 2026 | 8 |
| Coyne Terrance P. | EVP & CFO | 0Indirect | Aug 17, 2026 | 18 |
| Legorreta Pablo G. | CEO, Chairman of the Board | 1,307,820 | Aug 7, 2026 | 4 |
| Urist Marshall | EVP, Research & Investments | 8,252 | Aug 7, 2026 | 18 |
| Bassler Bonnie L | Director | 79,181 | Jun 30, 2026 | 5 |
| Weatherman Elizabeth H | Director | 13,103 | Jun 8, 2026 | 1 |
| Love Ted W | Director | 58,393 | Jun 8, 2026 | 1 |
| Hodgson David C | Director | 37,873 | Jun 8, 2026 | 1 |
| Norden Gregory | Director | 196,348 | Jun 8, 2026 | 2 |
| Coric Vlad | Director | 15,343 | Jun 8, 2026 | 1 |
| Ho Carole | Director | 4,545 | Jun 8, 2026 | 1 |
| Engelbert Catherine M. | Director | 55,673 | Jun 8, 2026 | 1 |
| Lloyd George W. | EVP, Investments & CLO | 0Indirect | Dec 19, 2025 | 4 |
| Fernandez Henry A | Director | 65,324 | Jun 30, 2025 | 0 |
| Desouza Errol B | Director | 81,352 | May 14, 2025 | 0 |
| Riggs Rory B | Director | 320,099 | Feb 22, 2024 | 0 |
| Giuliani Mario Germano | Director, 10% Owner | 2,477,520Indirect | Jan 3, 2024 | 0 |
| Avara Management Ltd | 10% Owner | 2,477,520Indirect | Jan 3, 2024 | 0 |
| Skyeline Management Ltd | 10% Owner | 7,795,072Indirect | Dec 7, 2022 | 0 |
| MGG Strategic SICAF SIF S.A. - MGG Strategic | 10% Owner | 7,879,374Indirect | Dec 5, 2022 | 0 |
| MGG Strategic SICAF SIF S.A. | 10% Owner | 7,879,374Indirect | Dec 5, 2022 | 0 |
| Reddoch James F. | EVP & Chief Scientific Officer | 820,800Indirect | Sep 30, 2022 | 0 |
| GG 1978 Sicaf Sif S.A. - GG Strategic | 10% Owner | 21,426,170Indirect | Sep 22, 2022 | 0 |
| GG 1978 Sicaf Sif S.A. | 10% Owner | 21,426,170Indirect | Sep 22, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 (view filing) | May 14 | 1 day | Norden GregoryDirector | SSaleClass A Ordinary Shares | −3.04K | $53.00 | −$161.4K | −1.6%191.8K after | 10b5-1 |
| May 15, 2026 (view filing) | May 14 | 1 day | Urist MarshallEVP, Research & Investments | SSaleClass A Ordinary Shares | −13.7K | $53.06 | −$726.1K | −30.0%31.9K after | 10b5-1 |
| May 21, 2026 (view filing) | May 20 | 1 day | Urist MarshallEVP, Research & Investments | SSaleClass A Ordinary Shares | −13.7K | $52.75 | −$721.8K | −42.9%18.2K after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Coyne Terrance P.EVP & CFO | SSaleClass A Ordinary Shares | −64.4K | $53.98 | −$3.48M | −100.0%0 after | 10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −150.0K | $54.39 | −$8.16M | −21.1%559.4K after | 2 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 24 | 1 day | Urist MarshallEVP, Research & Investments | SSaleClass A Ordinary Shares | −9.10K | $55.18 | −$502.0K | −50.0%9.10K after | 10b5-1 |
| Jul 2, 2026 (view filing)4:08 PM ET | Jun 30 | 2 days | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −100.0K | $56.52 | −$5.65M | −17.9%459.4K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)4:08 PM ET | Jun 30 | 2 days | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −30.0K | $56.46 | −$1.69M | −42.9%40.0K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)4:10 PM ET | Jul 1 | 1 day | Urist MarshallEVP, Research & Investments | SSaleClass A Ordinary Shares | −9.10K | $55.88 | −$508.5K | −100.0%0 after | 10b5-1 |
| Aug 17, 2026 (view filing)5:01 PM ET | Aug 13 | 4 days | Coyne Terrance P.EVP & CFO | SSaleClass A Ordinary Shares | −11.0K | $58.68 | −$645.6K | −100.0%0 after | 2 lots10b5-1 |
| Aug 19, 2026 (view filing)4:20 PM ET | Aug 18 | 1 day | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −100.0K | $59.97 | −$6.00M | −21.3%370.4K after | 10b5-1 |
| Sep 24, 2026 (view filing)4:10 PM ET | Sep 22 | 2 days | Hite ChristopherEVP & Chairman, Partnering | SSaleClass A Ordinary Shares | −100.0K | $58.53 | −$5.85M | −27.0%270.4K after | 2 lots10b5-1 |